Lorcaserin - University of California at San Fransisco/Epygenix Therapeutics

Drug Profile

Lorcaserin - University of California at San Fransisco/Epygenix Therapeutics

Alternative Names: EPX 200

Latest Information Update: 09 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of California at San Francisco
  • Developer University of California at San Francisco; University of Colorado at Denver
  • Class Benzazepines; Obesity therapies; Small molecules
  • Mechanism of Action Serotonin 2C receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Dravet syndrome
  • New Molecular Entity No
  • Available For Licensing Yes - Dravet syndrome

Highest Development Phases

  • Phase II Dravet syndrome

Most Recent Events

  • 03 May 2017 Phase-II clinical trials in Dravet syndrome in USA (unspecified route) (Epygenix Therapeutics pipeline, May 2017)
  • 03 May 2017 Chemical structure information added
  • 25 Apr 2017 Lorcaserin - University of California at San Fransisco/Epygenix Therapeutics receives Orphan Drug status for Dravet syndrome in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top